21 Mar 2024

Update on AVA6000 Phase 1a Clinical Trial Progress

Investors | Therapeutics

18 Mar 2024

Result of General Meeting

Investors

05 Mar 2024

Result of REX Retail Offer

Investors

29 Feb 2024

Result of Placing

Investors

28 Feb 2024

Proposed REX Retail Offer

Investors

28 Feb 2024

Proposed Fundraise to progress Therapeutics Division pipeline

Investors

22 Jan 2024

Issue of Equity and Total Voting Rights

Investors

19 Jan 2024

Appointment of Christina Coughlin, M.D., Ph.D. as Head of Research and Development

Investors | Therapeutics

19 Dec 2023

Appointment of Chief Business Officer

Investors | Therapeutics

13 Dec 2023

ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data

Investors | Therapeutics